Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 2.71% | 170.48 | 0.7% | $1335.07m | |
| PFE | Pfizer Inc. | 0.07% | 37.31 | 0.9% | $1185.97m | |
| LLY | Eli Lilly & Co. | 0.31% | 213.00 | 1.1% | $1039.28m | |
| ABBV | AbbVie, Inc. | -1.53% | 108.81 | 1.9% | $741.94m | |
| AZN | AstraZeneca Plc | 0.80% | 54.44 | 1.2% | $706.03m | |
| BMY | Bristol-Myers Squibb Co. | -0.60% | 64.44 | 1.0% | $699.94m | |
| MRK | Merck & Co., Inc. | -1.06% | 80.29 | 0.7% | $695.02m | |
| ARCT | Arcturus Therapeutics Holdings, Inc. | -6.41% | 64.99 | 0.0% | $214.40m | |
| NVS | Novartis AG | -2.60% | 95.91 | 0.2% | $197.19m | |
| VTRS | Viatris, Inc. | -0.81% | 17.09 | 0.0% | $191.78m | |
| RPRX | Royalty Pharma Plc | 2.56% | 52.82 | 0.2% | $182.74m | |
| GSK | GlaxoSmithKline Plc | 0.82% | 39.24 | 0.2% | $162.70m | |
| GRTS | Gritstone Oncology, Inc. | -13.83% | 20.56 | 0.0% | $157.84m | |
| SNY | Sanofi | -0.97% | 49.15 | 0.2% | $137.10m | |
| TAK | Takeda Pharmaceutical Co., Ltd. | -0.98% | 18.19 | 0.0% | $84.77m |
Company Profile
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.